Results

Total Results: 2,418 records

Showing results for "risks".

1. Archived: Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Evidence Summary: Menopausal Hormone Therapy: Preventive Medication, 2002 and 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/postmenopausal-hormone-replacement-therapy-for-primary-preve/v2-menopausal-hormone-therapy-preventive-medicatio
   August 21, 2002 - studies including three meta-analyses (relative risks range from 1.21 to 1.40). 71-73 Risk increases … with longer duration of use (relative risks range from 1.23 to 1.35 based on all six meta-analyses that … for breast cancer (relative risks range from 0.85 to 1.14 from 8 meta-analyses). 40 , 71-77 No meta-analyses … Except for CHD, rates are similar when WHI hazard ratios rather than relative risks from our review are … In many cases, a variety of relative risks was available for certain outcomes, and we selected a value

2. Archived: Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Evidence Summary: Menopausal Hormone Therapy: Preventive Medication, 2002 and 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/postmenopausal-hormone-replacement-therapy-for-primary-preve/menopausal-hormone-therapy-preventive-medication-2002-2005
   August 21, 2002 - studies including three meta-analyses (relative risks range from 1.21 to 1.40). 71-73 Risk increases … with longer duration of use (relative risks range from 1.23 to 1.35 based on all six meta-analyses that … for breast cancer (relative risks range from 0.85 to 1.14 from 8 meta-analyses). 40 , 71-77 No meta-analyses … Except for CHD, rates are similar when WHI hazard ratios rather than relative risks from our review are … In many cases, a variety of relative risks was available for certain outcomes, and we selected a value

3. Postmenopausal Hormone Replacement Therapy for the Primary Prevention of Chronic Conditions: A Summary of the Evidence for the USPSTF (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/sQ7hREGwnBm8Wh-LEFWP4F
   October 01, 2002 - studies including 3 meta- analyses (relative risks range from 1.21 to 1.40).71-73 Risk increases with … longer duration of use (relative risks range from 1.23 to 1.35 based on all 6 meta- Postmenopausal … for breast cancer (relative risks range from 0.85 to 1.14 from 8 meta-analyses).40,71-77 No meta-analyses … Except for CHD, rates are similar when WHI hazard ratios rather than relative risks from our review are … In many cases, a variety of relative risks was available for certain outcomes, and we selected a value

4. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the USPSTF (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/j69Hq5ALvzg74e-ngkzSep
   April 01, 2016 - outcome, we calcu- lated a range of expected event rates after aspirin in- tervention using the pooled relative … Baseline Estimates of Major Bleeding Risks (Trial vs. … Risk for Outcome, events per 1000 person-years Relative Risk (95% CI) Events Caused per 1000 Person-Years … as reported by included cohort studies. ¶ Using cohort baseline risk and trial relative risks to estimate … why persons with these risks have been excluded from trials.

5. Evidence Summary: Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/menopausal-hormone-therapy-preventive-medication
   December 12, 2017 - risk of a beneficial or harmful change in risks (eg, increase or reduction of cardiovascular events) … Absent meta-analytic estimates, relative risks of outcomes of interest were based primarily on a recent … WHIMS did not find an elevated risk of mild cognitive impairment. 72 Based on the WHI data, risks for … risks instead of hazard ratios. … Relative risks (RRs) were calculated to determine absolute risk reductions and increases presented in

6. Archived: Evidence Summary: Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/menopausal-hormone-therapy-preventive-medication-december-2017
   December 12, 2017 - risk of a beneficial or harmful change in risks (eg, increase or reduction of cardiovascular events) … Absent meta-analytic estimates, relative risks of outcomes of interest were based primarily on a recent … WHIMS did not find an elevated risk of mild cognitive impairment. 72 Based on the WHI data, risks for … risks instead of hazard ratios. … Relative risks (RRs) were calculated to determine absolute risk reductions and increases presented in

7. Evidence Summary: Bleeding Risks With Aspirin Use: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-bleeding-risks-with-aspirin-use/aspirin-to-prevent-cardiovascular-disease-and-cancer
   April 11, 2016 - outcome, we calculated a range of expected event rates after aspirin intervention using the pooled relative … events will vary depending on individual baseline bleeding risks. … why persons with these risks have been excluded from trials. … Level † Baseline Risk for Outcome, events per 1000 person-years Relative Risk (95% CI) Events … ¶ Using cohort baseline risk and trial relative risks to estimate events caused or prevented.

8. Archived: Evidence Summary: Bleeding Risks With Aspirin Use: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-bleeding-risks-with-aspirin-use/aspirin-to-prevent-cardiovascular-disease-and-cancer-april-2016
   April 11, 2016 - outcome, we calculated a range of expected event rates after aspirin intervention using the pooled relative … events will vary depending on individual baseline bleeding risks. … why persons with these risks have been excluded from trials. … Level † Baseline Risk for Outcome, events per 1000 person-years Relative Risk (95% CI) Events … ¶ Using cohort baseline risk and trial relative risks to estimate events caused or prevented.

9. Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2013
   September 15, 2013 - that treatment with tamoxifen or raloxifene can significantly reduce the relative risk (RR) for invasive … Breast Cancer Prevention Trial; IBC = invasive breast cancer; WHI = Women's Health Initiative; RR = relative … Breast Cancer Prevention Trial; IBC = invasive breast cancer; WHI = Women's Health Initiative; RR = relative … Breast Cancer Prevention Trial; IBC = invasive breast cancer; WHI = Women's Health Initiative; RR = relative … Breast Cancer Prevention Trial; IBC = invasive breast cancer; WHI = Women's Health Initiative; RR = relative

10. Evidence Summary: Hormone Therapy in Postmenopausal Persons: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary28/menopausal-hormone-therapy-preventive-medication
    November 01, 2022 - heterogeneity in effects between studies. 15 The outcome measure for all quantitative analyses was the relative … risk (RR) of a beneficial or harmful change in risks. … Most increased risks were not statistically different anymore after stopping hormone therapy. … ; NA, not applicable; NR, not reported; PE, pulmonary embolism; RCT, randomized clinical trial; RR, relative … applicable; NR, not reported; OR, odds ratio; PE, pulmonary embolism; RCT, randomized clinical trial; RR, relative

11. Zvvry6Wa4Sgj-Ejb3Brcvy (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/zVVRY6wa4Sgj-EJb3BRcVy
    November 01, 2013 - that treatment with tamoxifen or raloxifene can significantly reduce the relative risk (RR) for invasive … BCPT � Breast Cancer Prevention Trial; IBC � invasive breast cancer; RR � relative risk; STAR � Study … BCPT � Breast Cancer Prevention Trial; IBC � invasive breast cancer; RR � relative risk; STAR � Study … BCPT � Breast Cancer Prevention Trial; IBC � invasive breast cancer; RR � relative risk; STAR � Study … BCPT � Breast Cancer Prevention Trial; IBC � invasive breast cancer; RR � relative risk; STAR � Study

12. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/Rn7dRezgMx5syB-erQKoKt
    November 01, 2022 - for the US Preventive Services Task Force on the benefits and harms of hormone therapy in reducing risks … Participants using estrogen only compared with placebo had significantly lower risks for diabetes over … Risks per 10 000 persons were statistically significantly increased for gallbladder disease over 7.1 … (RR) of a beneficial or harmful change in risks. … applicable; NR, not reported; OR, odds ratio; PE, pulmonary embolism; RCT, randomized clinical trial; RR, relative

13. Archived: Postmenopausal Hormone Prophylaxis: Preventive Medication, 1996 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/postmenopausal-hormone-prophylaxis-preventive-medication-1996
    January 01, 1996 - largest and best-designed studies, the beneficial effect was most evident in current users of estrogen (relative … likely to benefit from therapy, but that risks may outweigh benefits among women at increased risk of … possible risks vs. potential benefits of therapy. … The balance of benefits and risks of estrogen therapy in women at increased risk of breast cancer is … Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis.

14. Modeling Study: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-modeling-study/aspirin-to-prevent-cardiovascular-disease-preventive-medication
    April 26, 2022 - In all scenarios, non-CRC benefits and harms were assumed to take effect immediately, and relative risks … estimate was lower and had a narrower confidence interval compared with the corresponding finding in 2016 (relative … for CRC incidence and affects fatal major gastrointestinal bleeding risks. … constant over time, but lifetime net benefits of aspirin would be higher if these relative risks decreased … CVD Parameter Relative

15. Using Aspirin for the Primary Prevention of Cardiovascular Disease (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/4fdC2JLwP_um_yZe4WZRaa
    April 01, 2009 - prevention studies of aspirin have found the following: Clinician Fact Sheet Aspirin use in women y 17% relative … relative risk reduction for MI y No effect on stroke or all-cause mortality y Talk With Your … Harms from aspirin include the risks of serious upper GI bleeding and hemorrhagic stroke. … this risk in women. … For these individuals, the benefits and risks of using aspirin are closely balanced.

16. Archived: Evidence Summary: Breast and Ovarian Cancer: BRCA Genetic Testing, September 2005 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer--brca-testing-ovarian-cancer-screeni
    September 15, 2005 - risks for breast and ovarian cancer in moderate- and high-risk groups. … All chemoprevention trials reported relative risk (RR) estimates, and the logarithm of the RR (logRR) … Sampling Distribution for Relative Risk When developing the outcomes table, the estimates of relative … Risk (95% CI) Type Treat- ment Group,  n Placebo Group, n Relative Risk … Relative Risks for Breast Cancer in Chemoprevention Trials Error bars represent 95% CIs.

17. Archived: Evidence Summary: Breast and Ovarian Cancer: BRCA Genetic Testing, September 2005 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-and-ovarian-cancer-brca-testing-screening-2005
    September 15, 2005 - risks for breast and ovarian cancer in moderate- and high-risk groups. … All chemoprevention trials reported relative risk (RR) estimates, and the logarithm of the RR (logRR) … Sampling Distribution for Relative Risk When developing the outcomes table, the estimates of relative … Risk (95% CI) Type Treat- ment Group,  n Placebo Group, n Relative Risk … Relative Risks for Breast Cancer in Chemoprevention Trials

18. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/3HxQuXnyqHpUKNqjB7hWBw
    September 01, 2005 - risks for breast and ovarian cancer in moderate- and high-risk groups. … All chemoprevention trials reported relative risk (RR) estimates, and the logarithm of the RR (logRR) … Combining all trials in a meta-analysis resulted in a relative risk for total breast cancer of 0.62 ( … The relative risk (0.39 [CI, 0.20 to 0.79]) was further reduced for estrogen receptor–positive breast … Relative risks for breast cancer in chemoprevention trials.

19. Treating Tobacco Use and Dependence - Patients Not Ready To Make A Quit Attempt Now (The “5 R’s”) (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/cjWWvkNrCHGUqu4jScs8Ak
    October 05, 2005 - The clinician can motivate patients to consider a quit attempt with the “5 R’s”: Relevance, Risks, Rewards … RISKS Ask the patient to identify potential negative consequences of tobacco use.

20. Archived: Evidence Summary: NSAIDs: Aspirin/NSAIDs for Prevention of Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-nsaids/aspirin-nsaids-for-prevention-of-colorectal-cancer-preventive-medication
    March 15, 2007 - Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Use of Nonaspirin … Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Duration of … We chose relative risk as the effect measure. … Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Use of Nonaspirin … Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Duration of